


Chun Can Capital Group



Company incorporated in Nevada (August 16, 1996)



Company business operations are acquisition, exploration, & operation of minerals with a focus on gold.



Company publicly traded on the OTC Markets with trading symbol "CNCN"

Acquisition

→ Casa Mining Limited (“Casa”)

On August 4th 2020 the Company approved and completed the purchase of 99.43% of Casa Mining Limited, a Mauritius company, and its DRC subsidiary Leda Mining Congo that holds 73.08% of the Misisi Gold Mining project with three million ounces of JORC Inferred Gold Resources at 2.16 Grams per ton.

→ Roded Gold Field in Southern Israel

→ Bele Mines Ltd. Gold Mining Project in Barbeton, South Africa

→ St. Antony Gold Mine in Western Ontario, Canada

→ Vector Resources, an Australian public company with two gold mines in the DRC

→ Citi Gold, Australian public company with its Towers Gold Project in Queensland, Australia

→ GV Gold Russia, the 6th largest gold mining producing company in Russia

Management Team

Dr. Fahed Merrehbi

Chairman H E

Zoli Macanda

Chief Executive Officer

James Mufaro,

COO, South Africa

Anthony Balme

Advisor

Share ownership

As of the date hereof, there are 230,000,000 common shares (par value \$0.0001 per share) and 20,000,000 preferred shares in the Company authorised and none-issued and outstanding as date hereof.

Chun Can Capital Group Common Stock Equity Ownership		
Shareholders	Number of Shares	Shareholding Percentage
Zurich Capital Funds Holdings Limited	114,400,000	52 %
Shareholders of Bele Holdings (Pty) Limited	12,500,000	7.5 %
Current Officers & Directors Group Total	126,900,000	%
External Shareholders	92,100,000	
Investors in Private Placement	5,000,000	2.5%
Other Public Holders	2,000,035	2.%
External Shareholders Group Total	97,000,035	%
POST PPM TOTAL:	225,000,000	100.00%

Use of proceeds

The net proceeds after all costs of this Offering shall be used for general operating purposes and to acquire the various gold mine projects and companies. The Company intends to apply these proceeds substantially as set forth herein, subject only to reallocation by Management in the best interests of the Company. Specifically, the Company's expenditures will include, but are in no way limited to, acquisition costs and general & administrative purposes to support rapid growth

→ The estimated \$100 Million Use of Proceeds:

Investment	Use of Proceeds	Investee Company
\$10.0 million	Working Capital	Casa Mining Limited, DRC
\$10.0 million	Share Purchase	Vector Resources DRC Gold
\$15.0million	Share Purchase	Bele Holdings, South Africa Gold
\$10.0 million	Joint Venture	Citi Gold Australia
\$15.0 million	Share Purchase	St Antony Mine, Canada Gold
\$10.0 million	Brokerage Fees	Securities Broker Fees
\$30 million	Working Capital	Chun Can Capital Group .
Total \$100 mil.		**Assumes fully subscribed.

Future funding plan (Bond)

In addition to the \$100 Million Stock Offering contemplated by this Offering Memorandum, the Company plans to issue a \$2.0 Billion Bond (the "Bond") with an interest coupon of 6%, and a ten year term. The Bond will mature at the end of 2030 and shall be listed publicly for trading and carry an insurance rating of A+ or better.

→ The Bonds proceeds are estimated to be used as

Investment	Use of Proceeds	Investee Company
\$1.3 Billion	Share Purchase	GV Gold, Russia
\$50 million	Gold Production	Casa Mining Ltd., DRC
\$100 million	Gold Production	Citi Gold Corp., Australia
\$50 million	Gold Production	Kazakhstan Gold
\$50 million	Gold Production	Bele Holdings, South Africa
\$100 million	Brokers Fees	Securities Brokers
\$40 million	Insurance Fee	Insurance Underwriter
\$200 million	Bond Interest Reserve	Bond Holders Trustee
\$100 million	Working Capital	Chun Can Capital Group .
Total \$2 Billion		

Risks

An investment in the Shares offered hereby involves significant risks including that an investment in the Shares is illiquid and that no market may develop for the shares of the Company.

- Development Stage Risks
- No Minimum Offering Amount
- Dependence on Future Financing
- Arbitrary Offering Price
- Dilution
- Projections May Not Be Achieved
- New Venture; Loss of Entire Investment
- Competition
- Dependence on Management
- Management of Growth
- Protection of the Company's Projects
- Additional Restrictions on Liquidity
- Lack of Market for Securities of the Company
- Forward-Looking Statements

Contact

Chairman H E

Dr. H E Fahed Merrehbi

Chief Executive Officer

Zoli Macanda Simbodyal


Email: Zoli@beleholdings.com



ALTEROLA BIOTECH, INC.



Company incorporated in Nevada (July 21, 2008)



Company business operations are acquisition, exploration, & operation of minerals with a focus on gold.



Company publicly traded on the OTC Markets with trading symbol "ABTI"

The company overview


Alterola is currently raising capital investment of US \$50.0 million to complete acquisitions and for capital to be used to locate, evaluate, and acquire additional successful IPs and suite of strategic companies. Once ABTI is current and audits are complete it will submit a registration application for a Reg A+ filing to become effective to raise \$50.0 million round of capital.

Acquisition

- **Canna Investor**- 6 Magazines, Marketing and Consultation
- **Amsterdam CBD**- 200 stores by year end with 1500 Franchise requests in the USA
- **Mister Cannabis**- 13 stores and expectation to expand to 50 stores by year end
- **Hempire Farms**- 1012-acre Production /extraction/9 million in equity
- **Natures Dream- Canacopia** – Digital App much like Weed Maps
- **CBD Shops**- Kentucky 6 stores- Global Crush

Medical Cannabis: International Growth Trends

Source: Prohibition Partners



The Medical Cannabis Market in USA

In the US alone, 24.8 million people are eligible to receive a recommendation and purchase medical cannabis legally under state laws and approximately 1 million people do.

The five-year USA national market potential is \$20.2 billion, which is more than a 700 percent increase above the current national market value.

Management Team

Irving Aronson

Chairman

Larson Elmore

Chief Executive Officer

Peter E. Maddocks

Chief Financial Officer

Rene Lauritsen

Chief Operating Officer

Dr. Aubrey Oliver

Chief Medical Officer

Advisory Members

Gianluca Cicogna Mozzoni

Alexander Lightman

Mike Weiss

Director

Lalit Verma

Dheeraj Jain



Contact

USA

Corporat Office

340 S. Lemon Ave # 4041,
Walnut ,California 91789

London

Alterola Biotech Inc

Irving Aronson, Chairman

Email: Irvingaronson@gmail.com

Larson Elmore Chief Executive Officer

Email: projectstrategies1@gmail.com

Tel: 81-15537357

London

Alterola Biotech Inc

Maddocks Chief Financial Officer

Email: peter.maddocks@btinternet.com



Leaf

It's not a Mask.
It's *Freedom.*

Product

Detroit-based Redcliffe Medical has launched a breakthrough transparent face mask with state of the art N99+ HEPA-Carbon filtration, powered by optional UV self-sterilization and active ventilation. Embodied in a design inspired by nature and natural transpiration of leaves, It's efficient yet minimalistic while allowing face unlock on Smartphones!

LEAF comes in different transparent, translucent and solid colors with 3 variants

→ LEAF-HEPA

→ LEAF-UV

→ LEAF-PRO



Profits & Plans

- Made revenue of 4.6 m in first 90 days
- Made profit of 3.5 m in first 90 days
- Forecasting to start sales on amazon
- Amazon projects one million mask sales per month at \$29.95. Leaf makes \$8 net per mask sale. So, forecast profit of 8 million per month or 96m for the next year
- If these sales achieved valuation will be minimum \$1 billion
- Can sell 25 % equity in private company Redcliff medical devices for \$20 m cash, equity investment into a profitable cash flow
- Company earning minimum \$3.5 m per quarter just off website sales without even amazon with amazon jumps as mentioned to 8 m per month. Dividend likely of \$40 m first year.
- Leaf has 26,000 thousand crowd fund investors its IOP will be a huge success as investors in all Covid-19 stocks are plentiful

Management Team

Alex Lightman

Co-Founder

Lalit Verma

Co-Founder

Contact

Leaf Healthcare

Website: www.leaf.healthcare

Email: pr@leaf.healthcare, Sales@leaf.healthcare

